What Divi's Laboratories does

Divi's Laboratories Limited is an Indian pharmaceutical company founded in 1990 and headquartered in Hyderabad. It manufactures Active Pharmaceutical Ingredients (APIs), advanced intermediates, and nutraceutical ingredients, and provides custom synthesis (CDMO) services to global generic and Big Pharma customers, exporting to more than 100 countries. The company's product portfolio spans over 30 commercial generic APIs (including Naproxen, Gabapentin, Dextromethorphan, Levetiracetam, Valsartan, Pregabalin, and Orlistat), custom-synthesized small molecules, high-potency APIs (HPAPIs), peptides manufactured via SPPS/LPPS/hybrid methods, biological buffers, and a full carotenoid and fat-soluble vitamin nutraceutical range.

The company operates three manufacturing facilities in India — Units I (Choutuppal, Telangana, ~5,700 M³), Unit II (Visakhapatnam, ~11,100 M³, claimed as the world's largest API facility), and Unit III (Kakinada, Phase I commissioned January 2025, ~1,800 M³) — for a combined capacity of approximately 18,600 M³ across 76 production blocks and more than 2,250 reactors. Manufacturing capability is differentiated by HPAPI containment (OEB-4/OEB-5), execution of high-energy, pyrophoric, azide, and high-pressure reactions, peptide chemistry, particle engineering (milling, micronization, polymorph control), and green-chemistry platforms (flow chemistry, biocatalysis, photochemistry). Quality and R&D infrastructure comprise over 2,500 QC/QA analysts and ~700 scientists across four R&D centers.

Divi's generates revenue through (a) direct B2B contracts for generic APIs, (b) long-term custom synthesis / CDMO agreements that constitute roughly 55% of sales at ~19% segment growth, and (c) nutraceutical ingredient supply to food, supplement, feed, and cosmetics manufacturers. Sales are conducted direct-to-pharma-enterprise through field sales, supported by regional offices in Florham Park, NJ and Basel, Switzerland, and brand presence at CPHI India, CPHI Milan, CPHI China, and Tides Europe. The company lists 12 of the top 20 global pharmaceutical companies as 10+ year custom-synthesis partners and has cleared 42+ cGMP audits across USFDA, EU GMP, Health Canada, TGA, ANVISA, PMDA, MFDS, and COFEPRIS. Publicly listed on NSE/BSE (DIVISLAB) since 2003, the company is led by founder-Chairman and Managing Director Dr. Murali K. Divi and CEO Dr. Kiran S. Divi.

Name

Divi's Laboratories

Legal name

Divi's Laboratories Limited

Website

https://divislabs.com

Company type

Public

Founded year

1990

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Divi's Laboratories is an Indian API manufacturer and CDMO producing generic active pharmaceutical ingredients, custom synthesis services for Big Pharma, and nutraceutical carotenoids and vitamins for pharmaceutical, food, supplement, feed, and cosmetics customers in over 100 countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Active pharmaceutical ingredients
• Custom synthesis CDMO
• Generic API manufacturing
• Nutraceutical ingredients
• Peptide synthesis

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Infrastructure, Personnel, Others

Revenue model

1. Generic APIs: Manufacturing and sale of generic active pharmaceutical ingredients including Naproxen, Dextromethorphan, Gabapentin, Levetacetam, Valsartan, Pregabalin, and Orlistat. The company produces 30+ commercial APIs in volumes ranging from 10s to 1000s of tons annually, supplying customers in over 100 countries.
2. Custom Synthesis / CDMO: Contract development and manufacturing services for Big Pharma customers, providing custom synthesis of APIs, advanced intermediates, and regulatory starting materials. The segment accounts for approximately 55% of sales and delivers 19% growth. Long-term partnerships with 12 of top 20 Big Pharma companies.
3. Nutraceuticals: Production and sale of carotenoids and vitamins including Beta Carotene, Astaxanthin, Lycopene, Lutein, Vitamin D3, and Vitamin A. Supplies to food, dietary supplement, feed, and cosmetic industries with over 100 distinct product forms.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Divi's Laboratories is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and a Contract Development and Manufacturing Organization (CDMO). The company operates three business segments: (1) Generic APIs - manufacturing 30+ commercially available APIs such as Naproxen, Gabapentin, Dextromethorphan, Pregabalin and Valsartan; (2) Custom Synthesis - contract manufacturing services for Big Pharma covering small molecules, HPAPIs, peptides and biological buffers; and (3) Nutraceuticals - carotenoids and vitamins (Beta Carotene, Astaxanthin, Lycopene, Lutein, Vitamin A, D2, D3, E) supplied to food, dietary, feed and cosmetic industries.

Product overview

Divi's Laboratories operates as a Contract Development and Manufacturing Organization (CDMO) offering three distinct business segments: (1) Generic APIs - manufacturing and supply of over 30 commercially available active pharmaceutical ingredients; (2) Custom Synthesis - contract manufacturing services for Big Pharma including small molecules, HPAPIs, peptides, and biological buffers; and (3) Nutraceuticals - production of carotenoids and vitamins for nutritional, food, and feed industries. The company operates three manufacturing facilities in India with combined capacity exceeding 18,600 M³.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic APIs Manufacturing and supply of 30+ commercially available generic Active Pharmaceutical Ingredients including Naproxen, Dextromethorphan, Gabapentin, Levetiracetam, Valsartan, Pregabalin and Orlistat. Volumes range from 10s to 1000s of tons annually. The company holds 65-85% global market share in select molecules such as Naproxen and Gabapentin.
• Custom Synthesis / CDMO Services Contract Development and Manufacturing Organization (CDMO) services for Big Pharma, including custom synthesis of small molecules, high-potency APIs (HPAPIs), peptides (SPPS, LPPS, hybrid technologies) and biological buffers. Includes kilo-lab to commercial-scale manufacturing, peptide fragments from dipeptides to 14-mers, and capability to execute complex high-energy, pyrophoric, azide and high-pressure reactions up to 6 MT batches. Accounts for ~55% of sales.
• Nutraceutical Ingredients Production and supply of carotenoids and fat-soluble vitamins including Beta Carotene, Astaxanthin, Lycopene, Lutein, Vitamin A, Vitamin D2, Vitamin D3 and Vitamin E Acetate. Products supplied in liquid, beadlet and powder formats to food, dietary supplement, animal feed and cosmetic industries with application testing and customer formulation support.

Quantifiable outcome

• 65-85% global market share in Naproxen and Gabapentin molecules
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Top 20 Global Pharmaceutical CompaniescoreStrategic or Co-development PartnerDivi's maintains established relationships with 12 of the top 20 Big Pharma companies across US, Europe and Japan for over 10 years. These strategic partnerships involve custom synthesis of APIs, supply of generic APIs, and long-term contract manufacturing arrangements.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Laurus Labs: Indian-headquartered API and CDMO player offering generic APIs, custom synthesis, and contract manufacturing services. Directly comparable to Divi's across small-molecule API manufacturing, generic API portfolio, and growing CDMO exposure to Big Pharma.
• Dr. Reddy's Laboratories: Indian pharmaceutical company with substantial API manufacturing operations alongside branded and generic finished formulations. Comparable in custom synthesis capability, USFDA-inspected infrastructure, and global export footprint.
• Dishman Carbogen Amcis: India-headquartered CDMO offering API development and manufacturing including HPAPIs and complex chemistries. Directly comparable as a custom synthesis and API manufacturing peer serving global pharma customers.
• Hikal: Indian CDMO and API manufacturer supplying active ingredients, intermediates, and contract research services to global pharmaceutical and agrochemical companies. Comparable to Divi's in API manufacturing scale and CDMO service offerings.
• Piramal Pharma Solutions: Global CDMO offering API development and manufacturing, including high-potency and complex chemistries. Directly comparable as a CDMO serving Big Pharma with custom synthesis capabilities and Indian manufacturing base.
• Aurobindo Pharma: One of India's largest vertically integrated generic pharmaceutical manufacturers with significant API manufacturing capacity alongside finished dosage forms. Comparable to Divi's in API scale, generic molecule breadth, and US-focused regulatory footprint.
• Syngene International: Indian contract research and manufacturing organization (CRO/CDMO) providing API development, custom synthesis, and biologics services to global pharma. Comparable as an India-based CDMO serving global pharma customers with regulated manufacturing capabilities.
• Jubilant Pharmova: Indian pharmaceutical company with API manufacturing, CDMO services, and generics businesses. Comparable to Divi's in API capacity, regulated manufacturing, and contract manufacturing exposure to global pharma customers.

Broad incumbents

• WuXi AppTec: China-headquartered global CRO/CDMO with very large-scale API and small-molecule manufacturing services for Big Pharma. Comparable as a competing CDMO capacity provider in custom synthesis, though operating from a different (Chinese) manufacturing base.
• Teva Active Pharmaceutical Ingredients: Teva's API business operates one of the largest generic API manufacturing networks globally, supplying third-party customers. Comparable to Divi's as a large-scale, multi-product generic API manufacturer, though Teva APIs operates as part of the broader Teva group.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Divi's Laboratories